NASDAQ$JAGX
Jaguar Health Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported a 14% increase in combined net revenue for prescription and non-prescription products compared to Q2 2024, and an 11% increase compared to Q3 2023.
Jaguar Health reported a revenue of $3.1 million for Q3 2024, representing an increase of 14% compared to Q2 2024 and 11% compared to Q3 2023. The company is advancing its core programs, including the development of crofelemer and the commercial launch of Gelclair.
- Combined net revenue for Q3 2024 reached approximately $3.1 million, a 14% increase over Q2 2024 and an 11% increase over Q3 2023.
- Mytesi revenue was approximately $3.0 million in Q3 2024, representing an 8% increase over Q3 2023.
- The company initiated the commercial launch of Gelclair® in October 2024.
- Jaguar is initiating two Phase 2 trials in Q4 2024 and supporting multiple investigator-initiated proof-of-concept studies of crofelemer.
Headline financials
Revenue & EPS history
Jaguar Health · Revenue · Quarterly
$3.11M
Revenue by segment
Jaguar Health · $20.3M total across 2 segments · Q1 2026
- Human Health$19.9M—98.3%
- Animal Health$345K—1.7%
Forward guidance
Jaguar Health anticipates catalysts in its core programs over the next 6 months, including the development of crofelemer and the commercial launch of Gelclair. The board of directors has no intention of implementing a reverse split of the Company’s common stock.
Tailwinds
- Initiating two Phase 2 trials in Q4 2024.
- Supporting multiple investigator-initiated proof-of-concept studies of crofelemer.
- Results of IITs expected by the end of 2024 and throughout 2025.
- Ongoing U.S. commercial launch of Gelclair.
- No intention of implementing a reverse split of the Company’s common stock.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2024
-6.2%
Avg return
Earnings day
-10.0%
Avg return
5 days after
-12.3%
Avg return
30 days after
24%
11 / 45 earnings
Positive
+23.1%
Q3 2023
Best reaction
-36.4%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.4% | -9.6% | — | |
| Q1 2026 | -5.0% | -13.6% | -37.9% | |
| Q3 2025 | +2.9% | -32.0% | -33.1% | |
| Q2 2025 | -17.9% | -25.9% | -24.3% | |
| Q1 2025 | +4.8% | -22.5% | -36.5% | |
| Q4 2024 | +8.8% | -12.6% | +144.8% | |
| Q3 2024 | -4.6% | -10.2% | -11.1% | |
| Q2 2024 | -10.8% | +5.8% | -7.5% | |
| Q1 2024 | -12.2% | -10.7% | -78.7% | |
| Q4 2023 | -17.8% | -6.7% | +150.0% | |
| Q3 2023 | +23.1% | +31.3% | -46.1% | |
| Q2 2023 | -10.8% | -12.6% | -44.9% | |
| Q1 2023 | -31.7% | -32.2% | -28.6% | |
| Q4 2022 | -31.0% | -44.4% | -51.3% | |
| Q3 2022 | -6.7% | -13.3% | -25.3% | |
| Q2 2022 | -8.8% | -8.6% | -32.6% | |
| Q1 2022 | -7.1% | -1.4% | -15.5% | |
| Q4 2021 | -7.4% | +12.8% | +42.5% | |
| Q3 2021 | -16.7% | -20.7% | -35.1% | |
| Q2 2021 | -12.8% | -15.0% | -34.8% | |
| Q1 2021 | -2.4% | +4.7% | +37.8% | |
| Q4 2020 | +13.8% | +14.4% | -13.2% | |
| Q3 2020 | -5.9% | +2.0% | +108.4% | |
| Q2 2020 | -21.3% | -15.3% | -36.5% | |
| Q1 2020 | -1.4% | -0.4% | -1.4% | |
| Q4 2019 | -5.9% | -6.5% | +2.0% | |
| Q3 2019 | -36.4% | -37.9% | -45.0% | |
| Q2 2019 | -23.9% | -27.7% | -16.4% | |
| Q1 2019 | +0.6% | +4.1% | -60.4% | |
| Q4 2018 | -9.8% | -23.9% | -38.6% | |
| Q3 2018 | -4.3% | -8.5% | -33.2% | |
| Q2 2018 | -12.4% | -19.9% | -50.3% | |
| Q1 2018 | -4.4% | -5.7% | -26.6% | |
| Q4 2017 | +4.6% | -1.1% | -9.3% | |
| Q3 2017 | -2.4% | -5.0% | -32.2% | |
| Q2 2017 | -6.3% | -15.4% | -19.7% | |
| Q1 2017 | -1.2% | -0.4% | -16.4% | |
| Q4 2016 | -1.1% | +10.3% | +16.1% | |
| Q3 2016 | -1.9% | -18.8% | -15.8% | |
| Q2 2016 | +3.4% | -6.1% | -23.1% | |
| Q1 2016 | +0.6% | — | — | |
| Q4 2015 | +5.6% | — | — | |
| Q3 2015 | +8.0% | — | — | |
| Q2 2015 | -1.7% | — | — | |
| Q1 2015 | -7.4% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro